Erlotinib and rapamycin in a patient with pediatric anaplastic oligodendroglioma.

Sustained response to erlotinib and rapamycin in a patient with pediatric anaplastic oligodendroglioma.:

Sustained response to erlotinib and rapamycin in a patient with pediatric anaplastic oligodendroglioma.

Pediatr Blood Cancer. 2020 Oct 01;:e28750

Authors: Geben LC, Mobley BC, Brockman AA, Pastakia D, Naftel R, Ihrie RA, Esbenshade AJ

Abstract

One goal of precision medicine is to identify mutations within individual tumors to design targeted treatment approaches. This report details the use of genomic testing to select a targeted therapy regimen of erlotinib and rapamycin for a pediatric anaplastic oligodendroglioma refractory to standard treatment, achieving a 33-month sustained response. Immunohistochemical analysis of total and phosphorylated protein isoforms showed abnormal signaling consistent with detected mutations, while revealing heterogeneity in per-cell activation of signaling pathways in multiple subpopulations of tumor cells throughout the course of disease. This case highlights molecular features that may be relevant to designing future targeted treatments.



PMID: 33001573 [PubMed - as supplied by publisher]